Flupentixol is an antipsychotic drug of the thioxanthene group. It exists in two geometric isomers, the trans(E) and pharmacologically active cis(Z) forms. Flupentixol decanoate is one of the active ingredients found in injectable drug formulations: it is produced by esterification of cis(Z)‐flupentixol with decanoic acid.[A229083] Flupentixol is an antagonist of both D1 and D2 dopamine receptors.[A229083] Available as oral tablets or long-acting intramuscular injections, flupentixol is marketed under brand names such as Depixol and Fluanxol. It is approved for use in Canada and other countries around the world, but not in the US. It is used for the management of chronic schizophrenia in patients whose main manifestations do not include excitement, agitation or hyperactivity.[L31808] It has been marketed to manage symptoms of depression in patients who may or may not exhibit signs of anxiety.[L31928] In combination with [melitracen], flupentixol is used to manage symptoms of anxiety, depression, and asthenia.[L31923]
Synonyms
Flupentixol
Flupentixolum
Flupentixol dihydrochloride
Flupenthixol
Flupentixol decanoate
Flupenthixole
Flupentixolo
Brand Names
Fluanxol 3mg - Tab
Fluanxol Depot Inj 100mg/ml
Fluanxol Depot Inj 20mg/ml
Fluanxol Tab 3mg
Fluanxol 0.5mg - Tab
Flupentixol Decanoate Injection BP
Fluanxol Depot 2% -liq Im 20mg/ml
Fluanxol Tab 0.5mg
Fluanxol Depot 10%- Liq Im 100mg/ml
Indication
Flupentixol is indicated for maintenance therapy of chronic schizophrenic patients whose main manifestations do not include excitement, agitation or hyperactivity.[L31808] It is indicated for the management of depression in adult patients who may, or may not, also be showing signs of anxiety.[L31928] Flupentixol in combination with [melitracen] is indicated to manage symptoms of anxiety, depression, and asthenia in adults.[L31923]
Categories
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Agents producing tachycardia
Agents that produce hypertension
Anticholinergic Agents
Antidepressive Agents
Antipsychotic Agents
Antipsychotic Agents (First Generation [Typical])
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Dopamine D2 Receptor Antagonists
Drugs causing inadvertant photosensitivity
Heterocyclic Compounds, Fused-Ring
Highest Risk QTc-Prolonging Agents
Muscarinic Antagonists
Nervous System
Neurotoxic agents
Neurotransmitter Agents
P-glycoprotein inhibitors
Photosensitizing Agents
Piperazines
Psycholeptics
Psychotropic Drugs
QTc Prolonging Agents
Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
